RxDoctor Payments Data

Tanja Roth

Psychiatric/Mental Health · Topeka, KSNPI 1316018518

Payments from drug & device makers

$3,029in general payments, 2019–2025

Across 136 payments — averaging $22.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$635
  • Alkermes, Inc.$582
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$434
  • Otsuka America Pharmaceutical, Inc.$421
  • Teva Pharmaceuticals USA, Inc.$285
  • Johnson & Johnson$233
  • plus $440 from 10 others

What the payments were for

  • Food & beverage$2,98298%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,029 in reported general payments places this provider in the 80th percentile of 404 psychiatric/mental health providers in Kansas.

See all psychiatric/mental health providers in Kansas

Medicare billing

Part B allowed, 2024
$19,043
Medicare patients
70
Services billed
218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate78$284,056
Invega TrinzaPaliperidone Palmitate23$231,835
Austedo XrDeutetrabenazine32$195,602
IngrezzaValbenazine Tosylate18$143,844
Abilify MaintenaAripiprazole48$139,559
AustedoDeutetrabenazine12$136,830
VraylarCariprazine Hcl74$108,710
RexultiBrexpiprazole31$49,322
LybalviOlanzapine/Samidorphan Malate17$27,797
Aripiprazole182$21,758
Lurasidone Hcl35$8,460
Paliperidone ErPaliperidone25$8,362
Quetiapine Fumarate ErQuetiapine Fumarate32$7,269
Divalproex Sodium ErDivalproex Sodium49$5,497
Asenapine Maleate22$4,808

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$233$515,891101 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo$285$332,43144 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$421$188,88179 claims
Neurocrine Biosciences, Inc.Ingrezza$15$143,84418 claims
AbbVieVraylar$635$108,71074 claims
Alkermes, Inc.Lybalvi$582$27,79717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 404 psychiatric/mental health providers in Kansas.

Other psychiatric/mental health in Topeka

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →